Key result
Gene editing technologies targeting key lipid metabolism genes such as PCSK9, LDLR, and ANGPTL3 show promising potential for sustained lipid reduction in pre-clinical and early clinical studies.
Why the study?
Existing dyslipidemia therapies are hindered by long-term adherence challenges, prompting interest in enduring solutions like gene editing for sustained lipid control.
Does gene editing provide safe and effective long-term control of dyslipidemia?
Does gene editing provide safe and effective long-term control of dyslipidemia?
Gene editing technologies like CRISPR/Cas9 offer a promising approach for long-term control of dyslipidemia by directly modifying genes involved in lipid metabolism.
Gene editing for dyslipidemia remains experimental; leaves open clinical translation and long-term safety data.
Dyslipidemia, characterized by abnormal lipid levels in the blood, significantly escalates the risk of atherosclerotic cardiovascular disease and requires effective treatment strategies. While existing therapies can be effective, long-term adherence is often challenging. There has been an interest in developing enduring and more efficient solutions. In this context, gene editing, particularly clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, emerges as a groundbreaking approach, offering potential long-term control of dyslipidemia by directly modifying gene expression. This review delves into the mechanistic insights of various gene-editing tools. We comprehensively analyze various pre-clinical and clinical studies, evaluating the safety, efficacy, and therapeutic implications of gene editing in dyslipidemia management. Key genetic targets, such as low-density lipoprotein receptor (LDLR), proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein 3 (ANGPTL3), apolipoprotein C3 (APOC3), and lipoprotein (a) (Lp(a)), known for their pivotal roles in lipid metabolism, are scrutinized. The paper highlights the promising outcomes of gene editing in achieving sustained lipid homeostasis, discusses the challenges and ethical considerations in genome editing, and envisions the future of gene therapy in revolutionizing dyslipidemia treatment and cardiovascular risk reduction.
No takes yet. Share an insight, caveat, or question.
Zadeh et al. (2024) conducted a review in Dyslipidemia. Gene editing (CRISPR/Cas9, base editing, etc.) was evaluated. Gene editing technologies targeting key lipid metabolism genes such as PCSK9, LDLR, and ANGPTL3 show promising potential for sustained lipid reduction in pre-clinical and early clinical studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: